IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Ashkenazi et al.

Docket No.:

39780-2730P1C44

Serial No.:

09/997,428

Group Art Unit:

1647

Filing Date:

November 15, 2001

Examiner:

Hamud, Fozia

For:

PRO1245 POLYPEPTIDES

EXPRESS MAIL LABEL NO.: EL 993 689 029 US

MAILING DATE: August 13, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MS: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that app (1) It is being filed within 3 months of the application filing date and is other continued prosecution application under § 1.53(d) OR
continued prosecution application under § 1.53(d)
OK
(2) It is being filed within 3 months of entry of a national stage OR
(3) It is being filed before the mail date of the first Office Action on the meri-
(4) It is being filed before the mailing of a first Office Action after the filing request for continued examination under § 1.114.

08/16/2004 JBRLINAN 00000043 081641 09997428

01 FC:1806

180.00 DA

X	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:						
		a certification as specified in §1.97(e) is provided below; or					
		a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or in the payment of other papers filed together with this statement.					
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:						
	A.	a certification as specified in §1.97(e) is completed below; and					
	B.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and					
⊠ Dated:	C.	a fee of \$180.00 as set forth in \$1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.					
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641 (Docket No. 39780-2730P1C44)</u> .						
			Respectfully submitted,				
	August	13, 2004	By: Saphne Reddy Daphne Reddy, Ph.D.				
			Daphne Reddy, Ph.D. UReg. No. 53,507				

HELLER EHRMAN WHITE & MCAULIFFE LLP

Customer No. 09157/35489

275 Middlefield Road Menlo Park, CA 94025-3506 Telephone: (650) 324-7000 Facsimile: (650) 324-0638

INFORMATION DISCLOSURE **STATEMENT**

PTO-1449

SERIAL NO.: ATTY. DOCKET NO.:

39780-2730P1C44

09/997,428

APPLICANT: Avi Ashkenazi, et al.

			FILING DATE: November	GROUP: 1645				
		U.	S. PATENT DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE		
		FOR	REIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	. COUNTRY	CLASS	SUBCLASS	YES	NO	
	OTHER DO	CUMENTS	(Including Author, Title, Date, P	ertinent Pa	iges, Etc.)			
1	Dayhoff, Accession N	No.: P_AAB652	280, WO 200073454-A1, Pub Date: D	December 7, 2	2000, Ashkenazi,	A.J., et al.		
	Dayhoff Accession No.: P_AAY44458, WO 9960160-A1, Pub Date: November 25, 1999, Yang, F., et al.							
1	✓ Dayhoff Accession No.: P_AAY66757, WO 9963088-A2, Pub Date: December 9, 1999, Baker, K, et al.							
Dayhoff Accession No.: P_AAY87288, WO 200000610-A2, Pub Date: January 6, 2000, Lal, P, et al.							••	
	Dayhoff Accession No.: AAL26217.1, Direct Submission, Submitted: October 16, 2000, Niimi, T., et al.							
1	Dayhoff Accession No.: P_AAW75868, WO 9833926-A1, Pub Date: August 6, 1998, Billing-Medel, P.A., et al.							
	Dayhoff Accession No.: AAK82942.1, Direct Submission, Submitted: June 15, 2001, Polyak, K., et al.							
• • •	Dayhoff Accession N	lo.: NP_443095	5.1, Proc. Natl. Acad. Sci. U.S.A., 98 (17), pp. 9796	-9801, 2001, Kro	p, 1.E., et	al.	
- 1	GenBank, Accession No.: P_AAZ65103, WO 9963088-A2, Pub Date: December 9, 1999, Baker, K., et. al.							
\	GenBank, Accession No.: P_AAF44249, WO 200073454-A1, Pub Date: December 7, 2000, Ashkenazi, A.J., et. al.							
U	GenBank, Accession No.: AX201348, WO 0153486-A, Pub Date: July 26, 2001, Ashkenazi, A.J., et. al.							
1	GenBank, Accession No.: P_AAZ29723, WO 9960160-A1, Pub Date: November 25, 1999, Yang, F., et. al.							
\int_{1}	GenBank, Accession No.: P_AAZ98173, WO 200000610-A2, Pub Date: January 6, 2000, Lal, P., et. al.							
·J			4621, WO 9833926-A1, Pub Date: Au					
V			4620, WO 9833926-A1, Pub Date: At					
J	GenBank, Accession	No.: AF08615	2, Direct Submission, Submitted: Aug	gust 24, 1998	, Woessner, J., et	al.		
1	GenBank, Accession	No.: AY04056	4, Direct Submission, Submitted: Jun	e 15, 2001, K	Crop, I.E., et al.			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

AUG 1 3 2004 55

INFORMATION DISCLOSURED STATEMENT PTO-1449			ATTY. DOCKET NO.: 39780-2730P1C44 APPLICANT: Avi Ashke	SERIAL NO.: 09/997,428				
	110-14-7		FILING DATE: November	GROUP: 1645				
		U.	S. PATENT DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	· NAME	CLASS	SUBCLASS	BCLASS FILING DATI		
		FOR	EIGN PATENT DOCUMENT	rs		ı		
EXAMINER'S	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRAN	SLATION	
INITIALS						YES	NO	
	OTHER DO	CUMENTS	(Including Author, Title, Date,	Pertinent Pa	iges, Etc.)			
	August (1999).		reat Cancer Predictive Testing",				•	
	Hyman, Elizabeth, et al., "Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer 1,2", Cancer Research 62 6240-6245, November (2002).							
·	Orntoft, Torben F., et al., "Genome-wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-Invasive and Invasive Human Transitional Cell Carcinomas", <i>Molecular & Cellular Proteomics</i> 1:37-45, (2002).							
·	Pollack, Jonathan R., et al., "Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors", <i>PNAS</i> Vol.99, 20:12963-12968, October (2002).							
			· · · · · · · · · · · · · · · · · · ·					
		TV					- 1	
	-							
FXAMINER			DATE CONSIDERED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.